Replies to post #251784 on Avid Bioservices Inc (CDMO)

[Bluerinse]

Great post! We are in the midst of the final shake down for our shares ....Hold on and buy if you can this is a once in a lifetime opportunity and we are very close
IMO

[biopharm]

BeiGene <> Jedd Wolchok <> Peregrine Pharmaceuticals

There are so many collaborations, as Steve King-CEO of Peregrine Pharmaceuticals had told us 2 years ago there were "dozens" and some doubted it (probably the same ones that are still so negative on Peregrine today). Since that time, we have now been told about MSK, to AstraZeneca, to NCCN and since I really don't like some getting fooled out there and allowing shares slip out of their hands.... just try to connect the dots with all the posts from the past.

I'll toss a little nugget in there again. MSK and Peregrine certainly attracted the attention of MSK Jedd Wolchok and how long was it after that did it take BeiGene to bring him on board? ... less than 4 months later. Now go back and read the prior post this is attached to and look at the secrecy of BeiGene and Peregrine... and read the words from Dr. Wolchok himself..

Hold them shares tight... someone is coming to get them... or have been trying : )

Interesting time on prior post ....May 29, 2015 Peregrine and MSK....then Sept 11, 2015 BeiGene brought on board Dr Jedd Wolchok

[biopharm]

May 28, 2015 and Sept 11, 2015

So what do these dates have in connection with Peregrine ....now being called Avid Bioservices ....= Dr Jedd Wolchok who has ready went public regarding PS Targeting advantages it brings increasing responders and removal of off target TOXICITIES

May 28, 2015 MSK and Peregrine announce collaboration

....just merely some months later it was BeiGene that brought on board Dr Jedd Wolchok

Sounds like there will be more action to come

[biopharm]

The studies at MSK will be performed under the direction of Taha Merghoub, Ph.D., Associate Attending Biologist, Melanoma and Immunotherapeutics Service, Ludwig Collaborative and the Swim Across America Laboratory, a part of the laboratory of Jedd D. Wolchok, M.D., Ph.D., a leader in the field of cancer immunotherapy. Dr. Wolchok serves as the Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation as well as an Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK.

"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system’s response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.

http://www.1stoncology.com/blog/2015/05/page/2/

...
....
Other scientists who contributed to this research include

Jennifer N. Durham, Bjarne R. Bartlett, Laveet K. Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S. Luber, Fay Wong, Nilofer S. Azad, Agnieszka A. Rucki, Dan Laheru, Ross Donehower, Atif Zaheer, Matthias Holdhoff, Christian Meyer, Shibin Zhou, Deborah Armstrong, Katherine M. Bever, Amanda N. Fader, Janis Taube, Franck Housseau, David Spetzler, Nickolas Papadopoulos, Kenneth W. Kinzler, James R. Eshleman and Robert A. Anders from Johns Hopkins;

George A. Fisher of Stanford University;

Todd S. Crocenzi of the Providence Cancer Center at Providence Health & Services, Portland, Oregon;

James J. Lee of the University of Pittsburgh Cancer Institute;

Tim F. Greten and Austin G. Duffy of the National Cancer Institute;

Kristen K. Ciombor of the Ohio State University Comprehensive Cancer Center;

Aleksandra D. Eyring, Bao H. Lam, Andrew Joe and S. Peter Kang of Merck;

Richard M. Goldberg of the West Virginia University Cancer Institute; and

Nianqing Xiao and David Spetzler of Caris Life Sciences.


Funding for this research was provided by the Swim Across America Laboratory at Johns Hopkins, the Ludwig Center for Cancer Genetics and Therapeutics, the Howard Hughes Medical Institutes, the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, the 2017 Stand Up To Cancer Colon Cancer Dream Team, the Commonwealth Fund, the Banyan Gate Foundation, the Lustgarten Foundation for Pancreatic Cancer Research, the Bloomberg Foundation, the Sol Goldman Pancreatic Cancer Research Center, Merck & Co. Inc., and the National Institutes of Health's National Cancer Institute (Gastrointestinal SPORE grant P50CA062924, P30CA006973, CA163672, CA43460, CA203891, CA67941, CA16058 and CA57345).
...
...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132022369

_______

Patents by Bert Vogelstein and again, any patent derived from PS Targeting collaborations where "after" such new knowledge derived from PS Targeting....shall have rights due back to Peregrine. Also notice even 6th patent down re: reduction in MDSCs and does new CEO Roger Lias even have a clue of knowledge about past PRs where PS Targeting proven to reduce MDSCs by "at least 40%" so will the new BODs go public and tell us if the research shows 85% reduction in MDSC ?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=116251345

https://patents.justia.com/inventor/bert-vogelstein

________

May 2018
https://www.immunooncology-congress.com/who-is-speaking/

[biopharm]

BeiGene <> Jedd Wolchok <> Peregrine Pharmaceuticals

There are so many collaborations, as Steve King-CEO of Peregrine Pharmaceuticals had told us 2 years ago there were "dozens" and some doubted it (probably the same ones that are still so negative on Peregrine today). Since that time, we have now been told about MSK, to AstraZeneca, to NCCN and since I really don't like some getting fooled out there and allowing shares slip out of their hands.... just try to connect the dots with all the posts from the past.

I'll toss a little nugget in there again. MSK and Peregrine certainly attracted the attention of MSK Jedd Wolchok and how long was it after that did it take BeiGene to bring him on board? ... less than 4 months later. Now go back and read the prior post this is attached to and look at the secrecy of BeiGene and Peregrine... and read the words from Dr. Wolchok himself..

Hold them shares tight... someone is coming to get them... or have been trying : )

....
...
....

Did Dr Jedd Wolchok work equally for Beigene and Peregrine Pharmaceutics as a Scientific Adviser ? Dr Wolchok can easily prove which drugs are PS Targeting ....

Two novel monoclonal antibodies targeting gal-9 –Gal-Nab 1 and 2—have been produced and characterized in this study. We report a protective effect of Gal-Nab1 and Gal-Nab2 on the apoptotic cell death induced by gal-9 in primary T cells. In addition, they inhibit late phenotypic changes observed in peripheral T cells that survive gal-9-induced apoptosis. Gal-Nab1 and Gal-Nab2 bind nearly identical, overlapping linear epitopes contained in the 213–224 amino-acid segments of gal-9. Nevertheless, they have some distinct functional characteristics suggesting that their three-dimensional epitopes are distinct. These differences are best demonstrated when gal-9 is applied on Jurkat cells where Gal-Nab1 is less efficient than Gal-Nab2 in the prevention of apoptotic cell death. In addition, Gal-Nab1 stimulates non-lethal phosphatidylserine translocation at the plasma membrane
..

...
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0202512

I wonder who is legally responsible for those that are stepping on the IP assets held at Peregrine ...now Avid Bioservices ....and being borrowed to Oncologie for the time being under their contract

[biopharm]

"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.
..
..
"A key focus of the Wolchok Lab's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize and destroy cancer. This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical and translational work will potentially guide the design of the next generation of clinical studies with bavituximab," said Dr. Merghoub.

"We are delighted to be working with a world-renowned pioneer and leader in the immuno-oncology space, recognizing that there remains significant research in order for more cancer patients to realize the benefits of combination immune therapy," said Jeff T. Hutchins, Ph.D., VP of Preclinical Research at Peregrine. "Our internal and collaborative research presented over the last year has established a robust foundation of PS-targeting activity on which to initiate this next chapter in PS research and development."
...
..

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=915472

Looks like Oncologie did not offer Dr Jedd Wolchok enough monies to further PS Targeting on all fronts or maybe Dr Wolchok was given enough monies to not bother with what he discovered ...in regards to PS Targeting patents